The BOADICEA model of genetic susceptibility to breast and ovarian cancer

被引:336
作者
Antoniou, AC
Pharoah, PPD
Smith, P
Easton, DF
机构
[1] Strangeways Res Lab, Canc Res UK, Genet Epidemiol Unit, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England
[2] Univ Cambridge, Canc Res UK, Human Canc Genet Grp, Dept Oncol, Cambridge, England
关键词
genetic counselling; BRCA1/2; risk modifiers; polygenic model;
D O I
10.1038/sj.bjc.6602175
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several genes conferring susceptibility to breast and ovarian cancer, notably BRCA1 and BRCA2, have been identified. The majority of the familial aggregation of breast cancer is, however, not explained by these genes. We have previously derived, using segregation analysis, a susceptibility model (BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) in which susceptibility to these genes is explained by mutations in BRCA1 and BRCA2 together with a polygenic component reflecting the joint multiplicative effect of multiple genes of small effect on breast cancer risk. Here, we consider the predictions made by this model. The overall familial risks of breast cancer predicted by this model are close to those observed in epidemiological studies. The predicted prevalences of BRCA1 and BRCA2 mutations among unselected cases of breast and ovarian cancer are also consistent with observations from population-based studies. These predictions are closer to the observed values than those obtained using the Claus model and BRCAPRO. The predicted mutation probabilities and cancer risks in individuals with a family history (FH) can differ markedly from those predicted by other models. We conclude that this model provides a rational basis for risk assessment in individuals with a FH of breast or ovarian cancer.
引用
收藏
页码:1580 / 1590
页数:11
相关论文
共 45 条
[1]   Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme [J].
Amir, E ;
Evans, DG ;
Shenton, A ;
Lalloo, F ;
Moran, A ;
Boggis, C ;
Wilson, M ;
Howell, A .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (11) :807-814
[2]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[3]   A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Stratton, MR ;
Peto, J ;
Ponder, BJ ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2002, 86 (01) :76-83
[4]   Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Ponder, BAJ ;
Easton, D .
GENETIC EPIDEMIOLOGY, 2001, 21 (01) :1-18
[5]   Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) [J].
Apicella, C ;
Andrews, L ;
Hodgson, SV ;
Fisher, SA ;
Lewis, CM ;
Solomon, E ;
Tucker, K ;
Friedlander, M ;
Bankier, A ;
Southey, MC ;
Venter, DJ ;
Hopper, JL .
BREAST CANCER RESEARCH, 2003, 5 (06) :R206-R216
[6]   Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease [J].
Beral, V ;
Bull, D ;
Doll, R ;
Peto, R ;
Reeves, G .
LANCET, 2001, 358 (9291) :1389-1399
[7]   BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [J].
Berry, DA ;
Iversen, ES ;
Gudbjartsson, DF ;
Hiller, EH ;
Garber, JE ;
Peshkin, BN ;
Lerman, C ;
Watson, P ;
Lynch, HT ;
Hilsenbeck, SG ;
Rubinstein, WS ;
Hughes, KS ;
Parmigiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2701-2712
[8]  
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[9]   Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study [J].
Brown, J ;
Buckley, D ;
Coulthard, A ;
Dixon, AK ;
Dixon, JM ;
Easton, DF ;
Eeles, RA ;
Evans, DGR ;
Gilbert, FG ;
Graves, M ;
Hayes, C ;
Jenkins, JPR ;
Jones, AP ;
Keevil, SF ;
Leach, MO ;
Liney, GP ;
Moss, SM ;
Padhani, AR ;
Parker, GJM ;
Pointon, LJ ;
Ponder, BAJ ;
Redpath, TW ;
Sloane, JP ;
Turnbull, LW ;
Walker, LG ;
Warren, RML .
MAGNETIC RESONANCE IMAGING, 2000, 18 (07) :765-776
[10]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003